Searching News Database: BioDelivery Sciences International
HSMN NewsFeed - 22 Feb 2016
Endo Announces Launch Of BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain Management
Endo Announces Launch Of BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain Management
HSMN NewsFeed - 26 Oct 2015
U.S. FDA Approves BELBUCA(TM) (buprenorphine) Buccal Film for Chronic Pain Management
U.S. FDA Approves BELBUCA(TM) (buprenorphine) Buccal Film for Chronic Pain Management
HSMN NewsFeed - 3 Dec 2013
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
HSMN NewsFeed - 15 Oct 2012
BioDelivery Sciences Announces the Launch of BREAKYL (BEMA Fentanyl) in the E.U.
BioDelivery Sciences Announces the Launch of BREAKYL (BEMA Fentanyl) in the E.U.
HSMN NewsFeed - 10 Jan 2008
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
HSMN NewsFeed - 5 Sep 2007
BDSI Secures U.S. Commercial Partnership for BEMA(TM) Fentanyl with Meda AB
BDSI Secures U.S. Commercial Partnership for BEMA(TM) Fentanyl with Meda AB
HSMN NewsFeed - 14 Aug 2007
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
HSMN NewsFeed - 14 May 2007
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
HSMN NewsFeed - 25 Apr 2007
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
Additional items found! 18
Members Archive contains
18 additional stories matching:
BioDelivery Sciences International
(Password required)
BioDelivery Sciences International
(Password required)